

Paper No. ____
Filed: March 15, 2016

Filed on behalf of: Mylan Laboratories Limited
By: Steven W. Parmelee
Michael T. Rosato
Jad A. Mills
WILSON SONSINI GOODRICH & ROSATI
701 Fifth Avenue, Suite 5100
Seattle, WA 98104-7036
Tel.: 206-883-2500

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN LABORATORIES LIMITED,
Petitioner,

v.

AVENTIS PHARMA S.A.,
Patent Owner.

Case No. IPR2016-00712
Patent No. 8,927,592

**PETITION FOR INTER PARTES REVIEW OF
U.S. PATENT NO. 8,927,592**

TABLE OF CONTENTS

	<u>Page</u>
I. Introduction	1
A. Brief Overview of the '592 Patent.....	3
B. Brief Overview of the Prosecution History	4
C. Brief Overview of the Scope and Content of the Prior Art	6
i. Winquist et al., Canadian J. of Urology, 15(1), 2008 (Ex. 1009)	6
ii. The TROPIC Listing (Ex. 1008)	7
iii. Pivot et al., Annals of Oncology 19:1547-1552, 2008 (Ex. 1010).....	8
iv. U.S. Patent No. 7,241,907 to Didier et al. (“Didier,” Ex. 1011)	8
v. Mita et al., Clin. Cancer Res., 15(2), 2009 (Ex. 1012).....	9
vi. Tannock et al., N. Engl. J. Med. 351, 2004, 1502-1512 (Ex. 1013).....	9
D. Brief Overview of the Level of Skill in the Art	9
II. Grounds for Standing.....	11
III. Mandatory Notices under 37 C.F.R. § 42.8.....	11
IV. Statement of the Precise Relief Requested	13
V. Statement of Non-Redundancy	14
VI. Claim Construction	14
A. “dose”	15
B. “prostate cancer that has progressed”	15

C.	“advanced metastatic disease”	16
D.	“castration-resistant” and “hormone-refractory”	16
E.	“C _{max} ”	16
F.	“CV”	17
G.	“A method for treating”	17
H.	“A method of increasing the survival of”	19
VII.	Background Knowledge in the Art Prior to October 29, 2009	20
VIII.	Detailed Explanation Of Grounds For Unpatentability.....	25
A.	Grounds Asserting Winquist and the Tropic Listing.	25
i.	[Ground 1] Claims 1-2, 5, 7-9, 12-13, 17-20, 22-25, and 27-29: Obvious over Winquist and the TROPIC Listing.	25
1.	Claim 1	25
2.	Claim 2	29
3.	Claims 7-9	30
4.	Claim 13	31
5.	Claims 17 and 20	31
6.	Claim 24	32
7.	Claim 27	32
8.	Claims 5, 19, 23, 25, and 29.....	34
9.	Claims 12, 18, 22, and 28.....	35
ii.	[Ground 2] Claims 3-4: Obvious over Winquist, the TROPIC Listing, and Didier.	38
iii.	[Ground 3] Claims 7-9: Obvious over Winquist, the TROPIC Listing, and Mita.	40
iv.	[Ground 4] Claims 10-11, 14, and 16: Obvious over Winquist, the TROPIC Listing, and Tannock.....	41
1.	Claims 10 and 11	41
2.	Claims 14 and 16	42
v.	[Ground 5] Claims 21, 26, and 30: Obvious over Winquist, the TROPIC Listing, and Pivot.	43
vi.	[Ground 6] Claim 15 : Obvious over Winquist, the TROPIC Listing, Pivot, and Tannock.	44

B.	Grounds Asserting Winquist and Pivot.	45
i.	[Ground 7] Claims 1-2, 5, 7-9, 12-13, and 17-30: Obvious over Winquist and Pivot.....	45
ii.	[Ground 8] Claims 3-4: Obvious over Winquist, Pivot, and Didier.	49
iii.	[Ground 9] Claims 7-9: Obvious over Winquist, Pivot, and Mita.....	50
iv.	[Ground 10] Claims 10-11 and 14-16: Obvious over Winquist, Pivot, and Tannock.	50
	1. Claims 10 and 11	50
	2. Claims 14-16	51
IX.	Phase III Clinical Data Are Not Required To Have a Reasonable Expectation of Success in an Obviousness Analysis	52
X.	No Unexpected Results.....	55
XI.	Conclusion.....	57
XII.	Payment of Fees under 37 C.F.R. §§ 42.15(a) and 42.103.....	58
XIII.	Appendix – List of Exhibits	59

...

I. INTRODUCTION

Mylan Laboratories Limited (“Petitioner”) requests review of U.S. Patent No. 8,927,592 to Gupta (“the ’592 patent,” Ex. 1001), that issued on January 6, 2015, and is currently assigned to Aventis Pharma S.A. (“Patent Owner”). This Petition demonstrates a reasonable likelihood that claims 1-5 and 7-30 of the ’592 patent are unpatentable for failing to distinguish over prior art.

Independent claim 1 is to a method of treatment that requires:

- administering 20 to 25 mg/m² of cabazitaxel, or its hydrate or solvate;
- in combination with a corticoid;
- to a patient with prostate cancer; and
- that the cancer progressed during or after treatment with docetaxel (Taxotere[®]).

The claimed method administers a known drug, in a known dosage range, in a known combination, with known activity against a known indication, to patients with that indication. Independent claim 27 specifies metastatic “castration resistant or hormone refractory” prostate cancer, and a prednisone or prednisolone corticoid.

The claimed method was published more than one year before the earliest alleged priority date of the ’592 patent. As just one example, Winqvist discloses an ongoing Phase III clinical study (“the TROPIC study”) in which 25 mg/m² of cabazitaxel (referenced as XRP-6258) was administered to patients in combination with prednisone (a corticoid) for treating hormone-refractory (castration-resistant) metastatic prostate cancer (“mCRPC”) previously treated with docetaxel. Ex. 1009.

As another example, the TROPIC Listing describes the same TROPIC study

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.